Additional long-term prospective studies in other populations, including subjects with various other health conditions, are needed to support our conclusion that increased adiponectin levels, as well as high baseline adiponectin levels, independently lower the risk of incident MetS. Here, ADIPOQ is linked to metabolic syndrome.